Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126084781 | 12608478 | 1 | I | 20160720 | 20160729 | 20160729 | EXP | CH-REGENERON PHARMACEUTICALS, INC.-2016-19802 | REGENERON | MUNK M.R.; CEKLIC L; EBNETER A; HUF W; WOLF S; ZINKERNAGEL M S. MACULAR ATROPHY IN PATIENTS WITH LONG-TERM ANTI-VEGF TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. ACTA OPHTHALMOLOGICA. 2016;1-8 | 0.00 | Y | 0.00000 | 20160729 | MD | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126084781 | 12608478 | 1 | PS | EYLEA | AFLIBERCEPT | 1 | UNK | 24 | DF | U | U | UNKNOWN | 125387 | INJECTION | |||||
| 126084781 | 12608478 | 2 | SS | RANIBIZUMAB | RANIBIZUMAB | 1 | UNK | 21 | DF | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126084781 | 12608478 | 1 | Neovascular age-related macular degeneration |
| 126084781 | 12608478 | 2 | Neovascular age-related macular degeneration |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126084781 | 12608478 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126084781 | 12608478 | Macular degeneration |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |